logo
  

CureVac Posts Sharply Wider Loss In Q1 - Quick Facts

Biopharmaceutical company CureVac N.V. (CVAC) reported Wednesday a pre-tax loss of 112.2 million euros for the first quarter of 2021, sharply wider than a pre-tax loss of 23.9 million euros in the prior-year quarter.

Financial result for the first quarter was a gain of 3.6 million euros, compared to a loss of 0.7 million euros for year-ago quarter. This net gain was driven mainly by foreign exchange gains, which were partly offset by negative interest on cash, which is being held in liquid funds to be available for use in the CVnCoV R&D and manufacturing activities.

Operating loss for the quarter also sharply widened to 115.8 million euros from 23.2 million euros last year, driven by higher research and development costs from our ongoing Phase 2/3 clinical trials of CVnCoV.

Revenues for the quarter more than tripled to 10.0 million euros from 3.1 million euros in the same quarter last year.

This increase was primarily driven by 9.1 million euros in revenue recognized under the collaboration agreement with GlaxoSmithKline plc (GSK), entered into in July 2020, for the research, development, manufacturing and commercialization of mRNA-based vaccines and monoclonal antibodies targeting infectious disease pathogens.

CureVac currently expects the first clinical trials for CV2CoV to start in the third quarter of 2021. CV2CoV is CureVac's second-generation vaccine candidate in its COVID-19 vaccine program, developed in collaboration with GSK.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
CVS Health is set to recruit qualified candidates to fill 25,000 clinical and retail jobs during a one-day national career event on Friday, September 24. This will enable CVS to meet the high demand for pharmacists, pharmacy technicians, nurses, and retail store associates to support flu season, COVID-19 vaccinations and testing. Twitter, Inc. (TWTR) announced Monday that it has entered into a binding agreement to settle the consolidated class action lawsuit commenced in 2016 in the United States District Court for the Northern District of California. Under the terms of the proposed settlement, Twitter will pay $809.5 million... Drug major Pfizer has again expanded the earlier two recalls of its anti-smoking Drug Chantix (Varenicline) in the form of tablets, to now include all the lots, for the potential presence of nitrosamine impurity, N-Nitroso- varenicline, at or above the FDA interim acceptable intake limit (ADI), the U.S. Food and Drug Administration or FDA said in a statement.
Follow RTT